Can we count your visit with Google Analytics? No ads, no profiles. Details
GENB
NASDAQNext earningsNov 10tomorrowAnalystsStrong Buy5+107%Health Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Clinical-stage generative-biology platform - AI-designed protein therapeutics. Feb 26 2026 NASDAQ IPO priced $16 ($400M gross / $369.3M net), Phase 3 SOLAIRIA-1/2 testing GB-0895 anti-TSLP in severe asthma. $516M cash post-IPO with ~$80M/qtr burn; runway into 1H 2028.
Amgen ($1.9B) + Novartis (>$1B) collabs anchor the validation but generate only $7.2M quarterly milestone revenue - most platform value remains back-end-loaded.
It reads our $GENB data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.